Thiazolidinediones as anti‐inflammatory and anti‐atherogenic agents
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
In the last few years, there has been increasing focus on the impact of interventions on cardiovascular outcomes in patients with type 2 diabetes. Insulin resistance and hyperglycaemia often co‐exist with a cluster of risk factors for coronary artery disease, but the underlying mechanisms leading to the development of such vascular complications are complex. The over‐production of free radicals in patients suffering from diabetes results in a state of oxidative stress, which leads to endothelial dysfunction and a greater risk of atherosclerosis. Moreover, inflammatory factors which play a critical role in atherothrombosis and plaque rupture are often found to be at elevated levels in this patient population. Thiazolidinediones (TZDs) are now routinely used to manage glucose levels, and have been suggested to influence other cardiovascular risk factors and therefore the pathways leading to macrovascular events. Consequently, recent studies have investigated the anti‐inflammatory and anti‐atherogenic properties of TZDs. The data available up to the present time, in the context of the emerging cardiovascular outcome profiles of rosiglitazone and pioglitazone, will be discussed here. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734 · cited 1×
“fold) during inflammatory processes, making it a useful marker of inflammation [131].”
BackgroundParadoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 2×
“The members of the FDA’s endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee recently reviewed a wider database of information and concluded that rosiglitazone was associated with a greater risk of myocardial ischemic events than placebo, metformin, or sulph…”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582 · cited 1×
“are markedly elevated during advanced heart failure [110].”
BackgroundYudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 1×
“In addition, the 3-year, prospective, randomized controlled trial (PROactive) provided evidence of a reduction in cardiovascular events with pioglitazone as opposed to the deleterious cardiovascular events associated with rosiglitazone that have been consistently highlighted in less robust analyses without cardiovascu…”
BackgroundAssociations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488 · cited 1×
“Large quantities of IL-6 are found in human atherosclerotic plaques [137], and increased levels of IL-6 appear to be predictive of future heart disease [138].”
BackgroundAntiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394
Ceriello, A., & Motz, E. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000122852.22604.78 · Cited by 1,378 · cited 1×
“Hyperlipidaemia, particularly increased plasma levels of free fatty acids (FFAs) and/or triglycerides, may also induce the generation of oxidative stress through the same pathways activated by hyperglycaemia [21,22], leading to endothelial dysfunction, insulin resistance and β-cell failure [23].”
BackgroundSelf-citationKern, P. A., Saghizadeh, M., Ong, J. M., Bosch, R. J., Deem, R., & Simsolo, R. B. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117899 · Cited by 1,305 · cited 1×
“insulin resistance can be decreased by subsequent weight loss [114,115].”
BackgroundRidker, P. M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.101.18.2149 · Cited by 934
Adiponectin Expression From Human Adipose Tissue
Kern, P. A., Di Gregorio, G. B., Lu, T., Rassouli, N., & Ranganathan, G. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1779 · Cited by 875 · cited 1×
“Adiponectin promotes insulin sensitivity [119,124], and patients with type 2 diabetes have lower levels of circulating adiponectin, thus contributing to the underlying state of insulin resistance and systemic inflammation [125].”
BackgroundPeroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 1×
“The TZDs, insulin-sensitizing agents that are used to treat patients with type 2 diabetes, may be able to modulate some of the processes associated with this ongoing inflammation and atherogenesis, as reported previously [6,7].”
BackgroundPrevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes
Green, K., Brand, M. D., & Murphy, M. P. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s110 · Cited by 490
Ceriello, A., Assaloni, R., Da Ros, R., Maier, A., Piconi, L., Quagliaro, L., Esposito, K., & Giugliano, D. (2005) · Circulation · doi:10.1161/01.cir.0000165070.46111.9f · Cited by 298 · cited 1×
“Hyperlipidaemia, particularly increased plasma levels of free fatty acids (FFAs) and/or triglycerides, may also induce the generation of oxidative stress through the same pathways activated by hyperglycaemia [21,22], leading to endothelial dysfunction, insulin resistance and β-cell failure [23].”
BackgroundSelf-citationThe DREAM trial – Authors' reply
Gerstein, H. C., Yusuf, S., & Bosch, J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69829-2 · Cited by 253
The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications
Ceriello, A. (2003) · Diabetologia · doi:10.1007/s00125-002-0931-5 · Cited by 181 · cited 1×
“patients with type 2 diabetes, and are likely to be related to their effects on free radical production [16].”
BackgroundSelf-citationTumor Necrosis Factor- in Sera of Obese Patients: Fall with Weight Loss
Dandona, P. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.8.2907 · Cited by 176
Bonora, E., Kiechl, S., Oberhollenzer, F., Egger, G., Bonadonna, R. C., Muggeo, M., & Willeit, J. (2000) · Diabetologia · doi:10.1007/s001250050024 · Cited by 140 · cited 1×
“Patients with type 2 diabetes generally have greater IMT measurements than controls, reflecting their higher cardiovascular risk profile [76,77].”
Background
Cited by
(1998) · PubMed · Cited by 2,737
Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease
Versari, D., Daghini, E., Virdis, A., Ghiadoni, L., & Taddei, S. (2009) · Diabetes Care · doi:10.2337/dc09-s330 · Cited by 516
Stress hormones: physiological stress and regulation of metabolism
Kyrou, I., & Tsigos, C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.08.007 · Cited by 431
IL-17 regulates adipogenesis, glucose homeostasis, and obesity
Zúñiga, L. A., Shen, W.-J., Joyce-Shaikh, B., Pyatnova, E. A., Richards, A. G., Thom, C., Andrade, S. M., Cua, D. J., Kraemer, F. B., & Butcher, E. C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001269 · Cited by 394
Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus
Burhans, M. S., Hagman, D. K., Kuzma, J. N., Schmidt, K. A., & Kratz, M. (2018) · Comprehensive Physiology · doi:10.1002/cphy.c170040 · Cited by 373
Metadata
- Authors
- Ceriello, A.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2007-11-07
- Volume
- 24
- Issue
- 1
- Pages
- 14-26
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1970161046
- Cited by
- 109
- References
- 24
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.